Key Developments: AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

11:59am EDT
Change (% chg)

-18.00p (-0.43%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Latest Key Developments (Source: Significant Developments)

AstraZeneca to collaborate with the University of Michigan
Wednesday, 17 Jun 2015 02:02am EDT 

AstraZeneca Plc:Announces a two-year research collaboration with the University of Michigan to advance the treatment of chronic kidney disease (CKD) through the improved understanding of the disease.Says the collaboration will tackle the challenging area of identifying novel targets for the treatment of CKD, focusing on the use of patient tissue and validation of preclinical models.  Full Article

AstraZeneca PLC announces phase III results for lesinurad in combination with febuxostat in tophaceous gout patients
Saturday, 13 Jun 2015 09:00am EDT 

AstraZeneca PLC:Announces results of its Phase III double-blind, multicenter, placebo-controlled trial CRYSTAL, investigating potential of lesinurad, a selective uric acid re-absorption inhibitor (SURI), when used in combination with xanthine oxidase inhibitor (XOI) febuxostat.Says results demonstrated that lesinurad in combination with febuxostat lowered serum uric acid (sUA) levels and reduced tophus area to a greater extent than febuxostat alone.Says lesinurad is investigational agent that inhibits uric acid transporter URAT1 in kidney, increasing uric acid excretion and thereby lowering sUA.Says lesinurad works in combination with febuxostat to provide a dual mechanism of action which increases excretion and decreases production of uric acid.  Full Article

AstraZeneca to collaborate with Lilly on solid tumours clinical trial
Friday, 29 May 2015 02:00am EDT 

AstraZeneca Plc:AstraZeneca and Lilly to collaborate on immuno-oncology combination clinical trial in solid tumours.Entered into a clinical trial collaboration to evaluate safety and preliminary efficacy of Astrazeneca's investigational anti-pd-l1 immune checkpoint inhibitor, medi4736.Phase I study is expected to establish safety and a recommended dosing regimen.  Full Article

AstraZeneca to invest in biologics manufacturing facility in Sweden
Monday, 18 May 2015 04:30am EDT 

AstraZeneca Plc:To invest in new biologics manufacturing facility in Södertälje, Sweden, to support accelerating biologics portfolio.New plant will be focused on filling and packaging of protein therapeutics.  Full Article

AstraZeneca PLC announces positive phase III results for two antibiotics, zinforo and investigational ceftazidime-avibactam
Monday, 27 Apr 2015 05:00am EDT 

AstraZeneca PLC:Presented positive Phase III data demonstrating the efficacy and safety of ceftazidime-avibactam (CAZ-AVI), an investigational antibiotic being developed to treat serious Gram-negative bacterial infections including complicated intra-abdominal infections.New Phase III data was also presented for ZINFORO (ceftaroline fosamil), an antibiotic approved for the treatment of adult patients with complicated skin and soft tissue infections (cSSTI) or community-acquired pneumonia (CAP).  Full Article

AstraZeneca PLC reaffirms FY 2015 guidance
Friday, 24 Apr 2015 02:00am EDT 

AstraZeneca PLC:Reiterates the guidance provided on Mar. 6, 2015.Sees FY 2015 total revenue to decline by mid single-digit percent at CER.Sees FY 2015 Core EPS to increase by low single-digit percent at CER.Says non-guidance information related to currency sensitivity.Based on current exchange rates, FY 2015 revenue is expected to decline by low double-digit percent.Sees FY 2015 Core EPS to be broadly in line with FY 2014.  Full Article

AstraZeneca PLC and Innate to collaborate in immuno-oncology
Friday, 24 Apr 2015 02:00am EDT 

AstraZeneca PLC:Announces that they have entered into a collaboration to accelerate and broaden the development of Innate Pharma SA's proprietary anti-NKG2A antibody, IPH2201, including in combination with MEDI4736, an anti-PD-L1 immune checkpoint inhibitor developed by MedImmune.Says currently in Phase II development, IPH2201 is a potential first-in-class humanised IgG4 antibody.Says NKG2A is a checkpoint receptor that inhibits the anti-cancer functions of Natural Killer (NK) and cytotoxic T-cells.  Full Article

Bina Technologies and AstraZeneca announce collaborative agreement for global deployment of Bina's genomic management solution
Tuesday, 21 Apr 2015 07:00am EDT 

AstraZeneca PLC:Enters into an agreement for AstraZeneca to become the first member to join the Bina Alliance Program and to further develop the Bina Genomic Management Solution (GMS).To utilize the Bina GMS as an enterprise platform to support its development work across three main therapeutic areas: oncology, cardiovascular and metabolic disease, and respiratory, inflammation and autoimmunity.Under the terms, AstraZeneca will adopt Bina GMS globally to support enterprise genomic data analysis and management.Bina in turn will provide AstraZeneca with direct access to its scientific and engineering teams to further develop the Bina GMS for pharmaceutical applications.  Full Article

AstraZeneca PLC announces selumetinib granted orphan drug designation by FDA
Friday, 17 Apr 2015 02:00am EDT 

AstraZeneca PLC:Says US Food and Drug Administration has granted Orphan Drug Designation for MEK inhibitor selumetinib, for the treatment of uveal melanoma.Uveal melanoma is rare disease in which cancer cells form in tissues of eye.It is most common primary intraocular malignancy in adults and comprises 5 pct of all melanomas1,2.Orphan Drug Designation programme provides orphan status to drugs and biologics, which are defined as those intended for the safe and effective treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US3.  Full Article

AstraZeneca PLC's Medimmune and Immunocore announces new collaboration to conduct immuno-oncology combination trials in melanoma
Thursday, 16 Apr 2015 02:02am EDT 

AstraZeneca PLC:Says that MedImmune, its global biologics research and development arm, has entered into a collaboration to conduct clinical trials in immuno-oncology with Immunocore Limited.Under the terms of agreement, Immunocore will conduct Phase Ib/II clinical trial combining MedImmune's investigational checkpoint inhibitors MEDI4736 (anti-PD-L1) and/or tremelimumab (anti-CTLA-4) with IMCgp100, Immunocore's lead T-cell receptor-based investigational therapeutic.Says for the potential treatment of patients with metastatic melanoma.MedImmune has an exclusive relationship with Immunocore for development of IMCgp100 in combination with MEDI4736 and/or tremelimumab.Will have first right of negotiation for the future commercial development of these combinations for tumours expressing glycoprotein 100 (gp100), a tumour-associated antigen.Immunocore and MedImmune will collaborate to establish a dosing regimen for IMCgp100 combined with MEDI4736 and/or tremelimumab within the Phase Ib study.The Phase II study will assess the safety and efficacy of the different combinations.  Full Article


AstraZeneca loses second top executive as Vectura gets new CEO

LONDON - AstraZeneca has lost a second senior executive in a fortnight with the departure of its respiratory and inflammatory medicines head James Ward-Lilley to become chief executive of lung drug specialist Vectura.

Search Stocks